Latest Conference Articles

Matthew Zirwas, MD, reviews the clinical discrepancies of certain JAK-targeting therapies and their role in dermatology patient outcomes.

Matthew Zirwas, MD, discusses the prospect of pairing JAK inhibitors like ruxolitinib cream with other disease-targeting options for conditions including vitiligo and alopecia areata.

These data, presented at RAD 2024, highlight the potential benefits of upadacitinib for adults and adolescents observed in the Measure Up 1 and Measure Up 2 studies.

Responses were highly durable throughout 4 years of bimekizumab treatment.

Jennifer L. Hsiao, MD, reviews the rapidly growing inventory of investigational drugs for HS.

Matthew Zirwas, MD, explains why he believes agents like ruxolitinib cream and upadacitinib have become the optimal treatments for atopic dermatitis, hidradenitis suppurativa, and more.

Significantly greater improvements were reported at week 2, which were sustained through week 12, in patients receiving the halobetasol propionate/tazarotene lotion compared with the vehicle cohort.

Sidbury covered the similarities and differences between the new guideline updates by the AAD on atopic dermatitis as well as differences with other organizations’ guidelines.

In new late-breaking data, alopecia patients’ real-world incidence of atopic dermatitis was highlighted by investigators.

Bourjeily told HCPLive at SLEEP 2024 that sleep issues, such as insomnia and restless legs syndrome, are the most common during the first and third trimester of pregnancy.

These data presented at RAD 2024 highlight the differences among eczema patient preferences in terms of administration modes, risk levels, and more.

The first line treatment for restless legs syndrome—dopamine agonists—may be making a patient’s condition worse in the long-term, Winkelman told HCPLive at SLEEP 2024.

An analysis of survey data from more than 200 patients with atopic dermatitis details treatment satisfaction and provider trust based on racial/ethnic backgrounds of patients.

Lisa Swanson, MD, explains how building resiliency is crucial for coping with burnout.

At SLEEP 2024, Kolla shared tips to help his fellow practitioners for improving patient outcomes when dealing with patients with both sleep issues and psychiatric illnesses.

Jennifer L. Hsiao, MD, discusses what the anticipated JAK inhibitors may provide to patients with HS if FDA-approved in the coming years.

This late-breaking data featured at RAD 2024 highlights several improvements in patient reported outcomes observed among atopic dermatitis patients, including itch relief.

Martin spoke about the barriers standing in the way of CPAP adherence in women with sleep apnea at SLEEP 2024.

This interview at RAD 2024 featured a discussion by Bissonnette of recent data related to 4 topical drugs for patients with atopic dermatitis.

At SLEEP 2024, Hartung discussed FloraWorks’ study finding patients on CBN had greater improvements in sleep quality than melatonin, but the difference was not significant.

In his RAD 2024 talk, Bissonnette presented recent data on 4 topical drugs for atopic dermatitis, including crisaborole and ruxolitinib.

Lisa Swanson, MD, discusses the pathogenesis of atopic dermatitis and why she does not recommend elimination diets for her pediatric patients.

Matthew Zirwas, MD, provides advice to dermatologists discussing the safety of JAK inhibitor therapies due to their controversial black box warning.

Jonathan Silverberg, MD, PhD, MPH, discusses how the results of the LEVEL UP trial impact treatment decisions for patients with moderate-to-severe atopic dermatitis.

LEVEL UP data presented at RAD 2024 provide additional insight into the phase 3b/4 trial comparing upadacitinib and dupilumab in atopic dermatitis beyond the primary endpoint.

At SLEEP 2024, Badr presented on novel treatments for central sleep apnea like phrenic nerve stimulation.

Patients with HS are getting a long-awaited influx of targeted therapies. Jennifer L. Hsiao, MD, discusses their immediate impact.

Treating eczema twice-daily with ruxolitinib cream, 1.5% led to positive results for children in the age range of 2 to 11 years.